FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Realm US

18,400 resources

Type: Text:

By Version

By Authority

 

Start Prev Rows 10400 - 10600 Next

PackageVersionIdentityName/TitleStatusFMMWGDateAuth
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.408CRC cancer M0_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.409CRC_Cancer_T1_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.410CRC_Cancer_T2_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.411CRC_Cancer_T3_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.412CRC_Cancer_T4_Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.413CRC Cancer N1 Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.414CRC Cancer N2 Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.415CRC Cancer N2b Stageactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.416KRAS_G12C_MVactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.417KRAS_G12C_PMactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.418KRAS_positiveactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.419Adagrasibactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.42Breast Canceractive2023-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.420cetuximab_therapyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.421Tamoxifen_therapyactive2024-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.423Endometrial Cancer Diagnosis ICD 10active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.425Endometrial Cancer Diagnosis ICD9CMactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.426Endometrial Cancer Diagnosisactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.428Localized_Endometerial_Stage Group SNOMEDactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.429Localized_Endometerial_Stage Group NCIMactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.431Endometrial_Sarcoma_Tumor_Histology_excactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.432Endometrial cancer M Stage (metastatic)active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.433Endometrial_M0_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.436Prior_therapy_Endometrialactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.437Paclitaxel_therapyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.441Carboplatin_therapyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.442Durvalumab_therapyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.444MMR_Gene_Lab_LOINCactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.447MMR_Gene_HGNCactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.449Endometrial_ Cancer N Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.451Endometrial_N0_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.453Endometrial_N1_N2_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.455Endometrial_T1_T3_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.456Endometrial_T3_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.458Endometrial_T4_Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.459Endometrial Cancer T Stageactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.46Endometrial Cancer ICD10active2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.460Localized_Endometerial_Stage Group_SNOMED/NCIMactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.461Metastatic Sites All CRCactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.462Metastatic Sites All CRC ICD 10active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.463Metastatic Sites All CRC ICD 9active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.464Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10)active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.465NTRK Repotrectinib Molecular Variantsactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.466NTRK_Gene_rearrangmentactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.467Prior_Systemic_therapy_Repotrectinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.468NTRK_Positiveactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.469NTRK_test_geneactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.47Systemic treatment for endometrial canceractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.470Tamoxifen_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.471Toremifene_trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.472Fulvestrant_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.473Elacestrantactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.474Anastrozole_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.475Leuprolide_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.476Abemaciclibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.477Palbociclibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.478Ribociclibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.479Carboplatin_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.48Endometrial Cancersactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.480Cisplatin_Trodelvyactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.481Cyclophosphamideactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.482Methotrexateactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.483Gemcitabineactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.484Capecitabineactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.485Eribulinactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.486Doxorubicinactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.487Vinorelbineactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.488Epirubicinactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.489Ixabepiloneactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.490Olaparibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.491Talazoparibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.492Entrectinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.493larotrectinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.494Alpelisibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.495Capivasertibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.496Pembrolizumabactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.497Dostarlimabactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.498Selpercatinibactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.499Everolimusactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.500Trastuzumab_deruxtecanactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.501Test 23active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.502All Metastatic sites Endometrial SNOMEDactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.503All Metastatic sites Endometrial ICD9active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.504All Metastatic sites Endometrial ICD10active2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.505All Metastatic sites Endometrialactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.506Create CRC_Cancer_T4a_Stageactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.507Create CRC_Cancer_T4b_Stageactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.508High Emetogenic Risk Chemotherapyactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.510InactiveFollowupactive2025-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.53MMR Gene Testingactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.54MSI Highactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.55MSI Highactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.6Orserduactive2023-08hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.61Stage IIB or lower and limitedactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.62Stage III or higheractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.63Stage III or higheractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.64Stage III or higheractive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.65Staging Unknownactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.66Staging Unknownactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.67Staging Unknownactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.68Jemperliactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.69Uterine Sarcomaactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.7Her2 Test For Orserduactive2023-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.70Tumor Histologyactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.71Platinum based therapyactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.72Prior Therapies for Tucatinibactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.73Tucatinibactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.74Colorectal Cancer ICD10active2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.75Colorectal Cancer ICD9active2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.76Colorectal Cancer ICD9 and ICD10active2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.78Advanced or Unresectable Colorectal Cancer Stagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.790 to IIIB Colorectal Cancer Stagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.80Colorectal Cancer M1 Stageactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.81RAS Genesactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.82RAS Gene Interpretation Negative LOINCactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.83RAS Gene Interpretation Negative SNOMEDactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.84RAS Gene Interpretation Negative NCMactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.85RAS Gene Negativeactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.86RAS Gene Interpretation Positive SNOMEDactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.87RAS Gene Interpretation Positive LOINCactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.88RAS Gene Positiveactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.89Her2 Testingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.90Patient Reasonactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.91MSI High NCIactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.92MSI Low SNOMEDactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.93MSI Low LOINCactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.94MSI Low NCIactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.95MSI Lowactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.96MMR Deficient NCIactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.97MMR Proficient SNOMEDactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.98MMR Proficient LOINCactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1260.99MMR Proficient NCIactive2024-01hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1262.3ICD9 Codes for HIV Diagnosisactive2023-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.1Inpatient Pneumonia Diagnosisactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.11Chest Imaging for Pneumonia, HCPCSactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.12Chest Imaging for Pneumonia Grouping Definitionactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.18ICD9 Abnormal Finding on Chest Imagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.19ICD10 Abnormal Finding on Chest Imagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.2ICD9 Pneumonia Definitionactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.20SNOMEDCT Abnormal Finding on Chest Imagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.21Abnormal Finding on Chest Imagingactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.22SNOMEDCT Pneumonia Definitionactive2023-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.23CAP Concurrent Infectionsactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.24CAP Pneumonia Diagnosticactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.25Antibiotic Usage for CAP Diagnosisactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.27Legionella Presence by Urine Antigen or DNAactive2024-09hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.29Broad Spectrum Antibiotics for MDROactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.3ICD10 Pneumonia Definitionactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.32CPT Transplants, Stem Cell and Solidactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.33HCPCS Transplant, Stem Cell and Solidactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.34ICD10CM Transplant, Stem Cell and Solidactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.35ICD10PCS Transplant, Stem Cell and Solidactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.37SNOMEDCT Transplant, Stem Cell and Solidactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.38Transplant, Stem Cell and Solidactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.39Antibiotic Usage for CAP Durationactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.40CAP Sepsis Diagnosticactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.41CAP Respiratory Failure Diagnosticactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.42MRSA Organism or Substance in Lab Resultsactive2024-12hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.8Systemic Antimicrobialsactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1264.9Chest Imaging for Pneumonia, CPTactive2023-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.1Problem Typeactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.10Information Source for Medication Adherence HSLOCactive2024-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.11Information Source for Medication Adherenceactive2024-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.14Unknown and Asked but Unknown (DAR)active2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.15Yes or No SCTactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.16Answer Set with Yes No and Unknownsactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.17Common LOINC Lab Codesactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.18Radiology Procedures (LOINC)active2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.21Universal Common LOINC Lab Ordersactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.22Route of Administration of Therapeutic Agentsactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.23Encounter Typeactive2025-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.27Social History Type (LOINC)active2025-05hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.28Social History Typeactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.3Smoking status comprehensiveactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.4Smoking Status Type LOINCactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.5Smoking Status Pack Years SCTactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.6Smoking Status Typeactive2024-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.7Information Source for Medication Adherence HL7 Role Codeactive2024-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.8Information Source for Medication Adherence ParticpationFunctionactive2024-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1267.9Information Source for Medication Adherence SCTactive2024-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.1Malnutritionactive2024-10hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.10Fractureactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.11Transplant Diagnosesactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.13Transplant Diagnoses ICD10CMactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.14Transplant Diagnoses SNOMED CTactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.15Respiratory Proceduresactive2025-04hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.3Diabetesactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.4Diabetesactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.5Diabetesactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.6Immobilityactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.7Smoking statusactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.8Obesityactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1272.9Hormone Therapyactive2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1282.1Drug Intervention Not Indicated/Contraindicatedactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1282.10Endotracheal Intubationactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1282.2Procedure Not Indicated/Contraindicatedactive2024-11hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1282.9Mechanical Circulatory Assist Deviceactive2025-02hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1289.1RXNormSBD0305active2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1289.2RXNormSCD0305active2025-03hl7
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1290.4Sequential Organ Failure Assessment SOFAactive2025-04hl7